Selection of patients for clomiphene citrate therapy.
Ninety-three infertile women were treated with clomiphene citrate alone or in combination with human chorionic gonadotropin (hCG) for absent or infrequent ovulation. The patients were divided into eight categories according to the diagnosis obtained: ovarian androgenic hyperplasia, adrenal androgenic hyperplasia, mixed ovarian and adrenal androgenic hyperplasia, hypothalamic anovulation, postpill anovulation, follicular phase defect, luteal phase defect, and amenorrhea-galactorrhea syndrome. Each group was analyzed individually to compare the ovulation and conception rates and the complications involved. A survey of the data presented in this study shows that the best response was noted in patients with ovarian androgenic hyperplasia. Patients with a functional pathologic adrenal component responded favorably when dexamethasone was used as an adjuvant to clomiphene therapy. Those with hypothalamic anovulation responded better when hCG was added to clomiphene therapy. Women with postpill anovulation as well as those with follicular phase defect were found to be good candidates for clomiphene therapy. In properly selected patients with poor luteal phase defect, hCG secured excellent results both in ovulation and conception. Patients with lactation amenorrhea failed to ovulate when treated with clomiphene alone.
D015068:17-Ketosteroids / Q000378:metabolism; D000307:Adrenal Gland Diseases / Q000188:drug therapy; D000568:Amenorrhea / Q000188:drug therapy; D000728:Androgens / Q000378:metabolism; D000858:Anovulation / Q000187:drug effects; D006063:Chorionic Gonadotropin / Q000627:therapeutic use; D002996:Clomiphene / Q000494:pharmacology / Q000627:therapeutic use*; D003276:Contraceptives, Oral / Q000009:adverse effects; D004717:Endometrium / Q000473:pathology; D005260:Female; D005687:Galactorrhea / Q000188:drug therapy; D006801:Humans; D006965:Hyperplasia / Q000188:drug therapy; D007031:Hypothalamus / Q000503:physiopathology; D007231:Infant, Newborn; D007247:Infertility, Female / Q000188:drug therapy*; D007986:Luteinizing Hormone / Q000378:metabolism; D010049:Ovarian Diseases / Q000188:drug therapy; D010060:Ovulation / Q000187:drug effects; D011247:Pregnancy
D015068:17-Ketosteroids; D000728:Androgens; D006063:Chorionic Gonadotropin; D003276:Contraceptives, Oral; D002996:Clomiphene; D007986:Luteinizing Hormone